RBS Upgrades AstraZeneca (AZN) to Buy
More News related to AZN
- U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
- AstraZeneca and the Philadelphia Department of Public Health Provide Free Medicines to Pennsylvania's Uninsured
- AstraZeneca (AZN) Submits NDA to U.S. FDA for Ticagrelor
- AstraZeneca Submits US New Drug Application for Ticagrelor (BRILINTA(TM)), an Investigational Antiplatelet Agent
- Results From Two Phase II Trials Add to Understanding of Ticagrelor (BRILINTA(TM)) and How it Works in the Body
More News related to Upgrades
- Hemispherx (HEB) Shares Breaking Out as $1 Technical Level Holds; Stock Up 23%
- Activision's (ATVI) Call of Duty Amasses $3 Billion in Global Sales
- Casino Stocks Tumble Sharply Amid Dubai Concerns (MGM, LVS, WYNN)
- Dubai Fallout ETF Trades
- Apple (AAPL) Shares to Open Below $200 as Dubai World Debt Weighs on Stocks
RBS upgrades AstraZeneca (NYSE: AZN) from Hold to Buy.
To see more analyst ratings on AZN Click Here.
AstraZeneca PLC (AstraZeneca) is engaged in the discovery, development, manufacturing and marketing of prescription pharmaceuticals and biological products for important areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation.
Related Categories
UpgradesStocks Mentioned
-1.09Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
